Spero Therapeutics (SPRO) Competitors $2.89 +0.09 (+3.21%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SPRO vs. CDXC, XNCR, ORIC, GHRS, TSHA, KROS, BCYC, IOVA, UPB, and VECTShould you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include ChromaDex (CDXC), Xencor (XNCR), ORIC Pharmaceuticals (ORIC), GH Research (GHRS), Taysha Gene Therapies (TSHA), Keros Therapeutics (KROS), Bicycle Therapeutics (BCYC), Iovance Biotherapeutics (IOVA), Upstream Bio (UPB), and VectivBio (VECT). These companies are all part of the "pharmaceutical products" industry. Spero Therapeutics vs. Its Competitors ChromaDex Xencor ORIC Pharmaceuticals GH Research Taysha Gene Therapies Keros Therapeutics Bicycle Therapeutics Iovance Biotherapeutics Upstream Bio VectivBio ChromaDex (NASDAQ:CDXC) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, community ranking, media sentiment, institutional ownership and valuation. Do institutionals and insiders hold more shares of CDXC or SPRO? 15.4% of ChromaDex shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 9.6% of ChromaDex shares are owned by insiders. Comparatively, 5.5% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, CDXC or SPRO? ChromaDex has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Do analysts rate CDXC or SPRO? ChromaDex presently has a consensus price target of $9.03, suggesting a potential upside of 0.00%. Spero Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 73.01%. Given Spero Therapeutics' higher possible upside, analysts plainly believe Spero Therapeutics is more favorable than ChromaDex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ChromaDex 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community believe in CDXC or SPRO? ChromaDex received 349 more outperform votes than Spero Therapeutics when rated by MarketBeat users. However, 69.67% of users gave Spero Therapeutics an outperform vote while only 65.03% of users gave ChromaDex an outperform vote. CompanyUnderperformOutperformChromaDexOutperform Votes55865.03% Underperform Votes30034.97% Spero TherapeuticsOutperform Votes20969.67% Underperform Votes9130.33% Does the media favor CDXC or SPRO? In the previous week, Spero Therapeutics had 5 more articles in the media than ChromaDex. MarketBeat recorded 5 mentions for Spero Therapeutics and 0 mentions for ChromaDex. Spero Therapeutics' average media sentiment score of 1.12 beat ChromaDex's score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment ChromaDex Neutral Spero Therapeutics Positive Which has preferable valuation and earnings, CDXC or SPRO? Spero Therapeutics has lower revenue, but higher earnings than ChromaDex. Spero Therapeutics is trading at a lower price-to-earnings ratio than ChromaDex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChromaDex$99.60M0.00-$4.94M$0.10N/ASpero Therapeutics$28.30M5.71$22.81M-$1.28-2.26 Is CDXC or SPRO more profitable? Spero Therapeutics has a net margin of 3.30% compared to ChromaDex's net margin of 1.62%. ChromaDex's return on equity of 4.85% beat Spero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ChromaDex1.62% 4.85% 2.70% Spero Therapeutics 3.30%4.03%2.21% SummaryChromaDex beats Spero Therapeutics on 10 of the 17 factors compared between the two stocks. Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRO vs. The Competition Export to ExcelMetricSpero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$161.58M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio41.298.6727.1419.96Price / Sales5.71262.53411.84157.63Price / Cash1.6265.8538.2534.64Price / Book1.436.597.064.69Net Income$22.81M$143.75M$3.23B$248.14M7 Day Performance15.60%0.82%0.80%0.95%1 Month Performance318.84%12.09%9.71%5.74%1 Year Performance110.95%4.46%32.12%14.73% Spero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPROSpero Therapeutics3.8847 of 5 stars$2.89+3.2%$5.00+73.0%+102.1%$161.58M$28.30M41.29150Short Interest ↑CDXCChromaDex2.6188 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120XNCRXencor4.1911 of 5 stars$8.58+7.3%$29.50+243.8%-57.2%$610.65M$127.23M-2.68280Positive NewsORICORIC Pharmaceuticals3.9082 of 5 stars$8.47+3.7%$19.17+126.3%+22.4%$602.12MN/A-4.6580Trending NewsAnalyst RevisionHigh Trading VolumeGHRSGH Research1.7731 of 5 stars$11.56-3.9%$30.43+163.2%+4.0%$601.44MN/A-14.6310Analyst RevisionTSHATaysha Gene Therapies3.8531 of 5 stars$2.79+3.0%$7.29+161.1%-32.2%$598.91M$7.22M4.43180Analyst ForecastAnalyst RevisionKROSKeros Therapeutics3.6591 of 5 stars$14.66+3.6%$37.00+152.4%-72.2%$595.42M$214.71M-2.81100Analyst DowngradeBCYCBicycle Therapeutics3.3634 of 5 stars$8.55+4.0%$25.00+192.4%-64.5%$592.12M$25.72M-2.60240Analyst RevisionIOVAIovance Biotherapeutics4.5276 of 5 stars$1.76+0.6%$13.30+655.7%-72.9%$587.72M$212.68M-1.18500Trending NewsUPBUpstream Bio1.943 of 5 stars$10.66+15.5%$56.50+430.0%N/A$573.44M$2.30M0.0038High Trading VolumeVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading Volume Related Companies and Tools Related Companies ChromaDex Alternatives Xencor Alternatives ORIC Pharmaceuticals Alternatives GH Research Alternatives Taysha Gene Therapies Alternatives Keros Therapeutics Alternatives Bicycle Therapeutics Alternatives Iovance Biotherapeutics Alternatives Upstream Bio Alternatives VectivBio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRO) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
